Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
The Stanford Health Care Center for Memory Disorders is encouraged that there is a new treatment option for certain patients with Alzheimer’s disease. On January 6, 2023, the FDA granted accelerated approval for lecanemab (LeqembiTM).
Open trials refer to studies currently recruiting participants or that may recruit participants in the near future. Closed trials are not currently enrolling, but similar studies may open in the future.
Closed trials are not currently enrolling, but may open in the future.